← All reports

The Endocrine Activity IndexTM Recurrence Risk (EAIRR) enhances risk stratification beyond the Recurrence Score® in cancer patients.

HealthcareScienceMay 7, 2026score 0.172 posts · 0 replies across 1 instances
Two posts from [email protected] announce a new publication in the European Journal of Cancer by Delphi Diagnostics. The manuscript claims that the Endocrine Activity IndexTM Recurrence Risk (EAIRR) improves risk stratification beyond the Recurrence Score® and is predictive. The posts promote the publication and its implications for cancer risk assessment.

Claims

The Endocrine Activity IndexTM Recurrence Risk (EAIRR) enhances risk stratification beyond the Recurrence Score® in cancer patients.
Parent: Medical ResearchEntity: Endocrine Activity IndexTM Recurrence Risk (EAIRR)Impact: positiveDate: May 7, 2026Target: The effectiveness of EAIRR in improving cancer risk assessment

Source posts

@[email protected]
Delphi Diagnostics Announces New Publication in the European Journal of Cancer Peer-reviewed manuscript demonstrates the Endocrine Activity IndexTM Recurrence Risk (EAIRR) enhances risk stratification beyond Recurrence Score® and is predictive… #Europe #EU #European https://www.europesays.com/europe/33932/
0 boosts · 0 favs · 0 replies · May 7, 2026
#europe#eu#european
@[email protected]
Delphi Diagnostics Announces New Publication in the European Journal of Cancer | Press Releases Peer-reviewed manuscript demonstrates the Endocrine Activity IndexTM Recurrence Risk (EAIRR) enhances risk stratification beyond Recurrence Score® and is predictive… #Europe #EU #European https://www.europesays.com/europe/33951/
0 boosts · 0 favs · 0 replies · May 7, 2026
#europe#eu#european